Vi­vid­ion 2.0? Ben Cra­vatt and Scripps team form a new chemo­pro­teomics biotech

By Jeff Jonker’s count, more than a dozen biotechs op­er­ate in the chemo­pro­teomics space, in which com­pa­nies like Vi­vid­ion Ther­a­peu­tics look to up­end small mol­e­cule drug dis­cov­ery.

Add Jonker’s lat­est up­start to the ta­ble. Af­ter launch­ing Vi­vid­ion, Ver­sant Ven­tures is back with what it calls a next-gen ap­proach to the field with Bel­har­ra Ther­a­peu­tics. A $50 mil­lion Se­ries A will kick things off for the small mol­e­cule de­vel­op­er.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER